[1]许杨.前列腺特异性抗原及其临床应用[J].国际放射医学核医学杂志,2000,24(5):201-205.
　XU Yang.Prostate specific antigen and its clinical apptication[J].International Journal of Radiation Medicine and Nuclear Medicine,2000,24(5):201-205.
点击复制

前列腺特异性抗原及其临床应用(/HTML)
分享到：

《国际放射医学核医学杂志》[ISSN:1673-4114/CN:12-1381/R]

卷:
24
期数:
2000年第5期
页码:
201-205
栏目:
综述
出版日期:
1900-01-01

文章信息/Info

Title:
Prostate specific antigen and its clinical apptication
作者:
许杨
100021 北京, 中国医学科学院肿瘤医院核医学基础室
Author(s):
XU Yang
Department of Nuclear Medicine, Cancer Institute Chinese Academy of Medical Science, Beijing 100021, China
关键词:
前列腺特异性抗原; 前列腺癌; 肿瘤标志物
Keywords:
Prostate-specific antigen; prostate neoplasma; tumor marker
分类号:
R730.45;R817.4
摘要:
前列腺特异性抗原(PSA)是一种单链糖蛋白,它由前列腺上皮细胞产生,分泌至前列腺管,因此精液中PSA含量很高,而正常人血清中含量很少。癌变时,患者PSA在血中的浓度升高。近年来,人们对PSA的生物学特征、检测方法、临床应用进行了大量的研究,取得了很大进展。PSA已成为最具有临床价值的肿瘤标志物之一,被应用于前列腺癌的临床诊断和监测。
Abstract:
Prostate-Specific Antigen (PSA), a serine proteases. is a glycoprotein consisting of a single polypeptide chain. Secreted exclusively by epithelial cells of the prostate gland, PSA is found largely in seminal plasma. Only a small amount of PSA can be found in normal serum. Serum PSA levels are found to be, considerably increased in prostate cancer patients. A number of studies on PSA have made great achievement on its biochemistry, analytical method and clinical application. PSA as one of the most important tumor marker. is used to help diagnosis and monitor the therapeutic efficacy of prostate cancer.

参考文献/References:

[1] Albert A, Chen YT, Thomas F, et al. Measerement of the proportion of free to total Prostate-specific antigen improves diagnostic the diagnostic gray zone of total prostate-specific antigen[J]. Urology, 1995, 46:187-194.
[2] Evacorey H, Sandra K, Michael J, et al. Prostate-specific antigen:characterization of epitopes by syn-thetic peptide mapping and inhibition studies[J]. J Urol, 1997, 43:575-584.
[3] Robert T, Harry G, Judith A, et al. Molecular forms of prostate-specific antigen and the human kallikrein gene family:a new ear[J]. Urology, 1995, 45:729-744.
[4] Baffa R, Moreno JG, Monne M, et al. A comparative analysis of prostate specific antigen gene sequence in benign and malignant prostate tissue[J]. Urology, 1996, 47:795-800.
[5] Polascik TJ, Oesterling JE, Partin AW. Prostate spe-cific antigen:a decade of discovery-what we have learned and where we are gong[J]. J Urol, 1999, 162:293-306.
[6] Dimitrios N, Eleftherios P. Diagnostic value of mole-cular forms of prostate-specific antigen for female breast cancer[J]. Clin Biol, 1996, 29:193-200.
[7] Fougia NK, Christofidis I, Strantzals N, et al. Physicochemical conditions affecting the formation/stability of serum complex and the determination of prostate-specific antigen[J]. Anticancer Res, 1999, 19:3315-3320.
[8] Yu H, Eleftherios P, Diamandis, et al. Prostate-spe-cific antigen in milk of lactating women[J]. Clin Chem, 1995, 41:54-58.
[9] Luxiong C, Anthony P, Thomas A, et al. Purification and characterization of prostate-specific antigen com-plexed to a1-antichymotrpsin:potential reference mate-rial for international standardization of PSA im-munoassays[J]. Clin Chem, 1995, 41:1273-1282.
[10] Carole C, Luong P, William K, et al. Evaluation of a two-site immunoradiometric assay for measuring non-complexed prostate-specific antigen[J]. Clin Chem, 1996, 42:1234-1249.
[11] Lilja M, Kin P, Timo P, et al. Dual-label one-step immunoassay for simultaneous measurement of free and total prostate-specific antigen concentrations and ratios in serum[J]. Clin Chem, 1995, 41:1115-1120.
[12] Barbara G, Theodore K. Quantitative reverse tran-scriptas-polymerase chain reaction for prostate-specific antigen M rna[J]. Clin Biochem, 1997, 31:391-397.
[13] Anderson JR, Strickland D, Corbin D, et al. Age-spe-cific ranges for serum prostate-specific antigen[J]. Urology, 1995, 46:54-57.
[14] Joseph G, Joel S, Michael C, et al. Age specific prostate specific antigen reference ranges:population specific[J]. J Urol, 1998, 159:444-448.
[15] Lein M, Stephan C, Jung K, et al. Relation of free PSA/total PSA in serum for differentiating between patients with prostatic cancer and benign hyperplasia of the prostate:which cutoff should be use?[J]. Can-cer Invest, 1998, 16:45-49.
[16] Eiji H, Kikuo N, Miho K, et al. Significance of serum free prostate specific antigen in the screening of prostate cancer[J]. J Urol, 1996, 156:1964-1968.
[17] Thomas H, Ted O, Judd W, et al. Comparison of serum prostate specific membrane antigen, prostat spe-cific antigen, and free prostate specific antigen level in radical prostatectomy patients[J]. J Urol, 1997, 42:107-114.

相似文献/References:

[1]郝玉美,贺欣,宋娜玲.前列腺癌干细胞分离方法研究进展[J].国际放射医学核医学杂志,2013,37(5):296.[doi:10.3760/cma.j.issn.1673-4114.2013.05.011]
　HAO Yu-mei,HE Xin,SONG Na-ling.Advanced research on separating prostate cancer stem cells[J].International Journal of Radiation Medicine and Nuclear Medicine,2013,37(5):296.[doi:10.3760/cma.j.issn.1673-4114.2013.05.011]
[2]徐慧琴,薛杨央,赵学峰,等.18F-FDG PET-CT诊断前列腺癌复发与转移的价值[J].国际放射医学核医学杂志,2011,35(2):81.[doi:10.3760/cma.j.issn.1673-4114.2011.02.004]
　XU Hui-qin,XUE Yang-yang,ZHAO Xue-feng,et al.Value of 18F-FDG PET-CT in diagnoss of prostate cancer recurrence and metastasis[J].International Journal of Radiation Medicine and Nuclear Medicine,2011,35(5):81.[doi:10.3760/cma.j.issn.1673-4114.2011.02.004]
[3]秦岚.前列腺癌近距离放射治疗的进展[J].国际放射医学核医学杂志,2005,29(4):159.
　QIN Lan.Evolution of brachytherapy for prostate carcinoma[J].International Journal of Radiation Medicine and Nuclear Medicine,2005,29(5):159.
[4]廖安燕,王俊杰.持续低剂量率照射治疗前列腺癌的生物学效应[J].国际放射医学核医学杂志,2005,29(4):190.
　LIAO An-yan,WANG Jun-jie.The biological effect of continuous low-dose rate irradiation for prostate cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2005,29(5):190.
[5]王俊杰.放射性粒子近距离治疗前列腺癌:临床篇[J].国际放射医学核医学杂志,2002,26(3):101.
　WANG Jun-jie.Radioactive seed implantation treatment for prostate carcinoma[J].International Journal of Radiation Medicine and Nuclear Medicine,2002,26(5):101.
[6]王宇.间质植入近距离照射治疗前列腺癌[J].国际放射医学核医学杂志,2001,25(5):233.
　WANG Yu.Interstitial implantation brachytherapy for the treatment of prostate carcinoma[J].International Journal of Radiation Medicine and Nuclear Medicine,2001,25(5):233.
[7]陈立波.钠/碘同向转运体与放射性碘治疗[J].国际放射医学核医学杂志,2001,25(6):258.
　CHEN Li-bo.The sodium/iodide symporter and radioiodide therapy[J].International Journal of Radiation Medicine and Nuclear Medicine,2001,25(5):258.
[8]陆汉魁,林祥通,刘家慧,等.乳腺癌和前列腺癌的类固醇受体显像研究现状[J].国际放射医学核医学杂志,1996,20(3):106.

备注/Memo

备注/Memo:
收稿日期:1998-11-20。
作者简介:许杨(1970-),女,北京人,中国医学科学院协和医大肿瘤研究所核医学基础室助理研究员,硕士,主要从事肿瘤标志物免疫分析。
更新日期/Last Update: 1900-01-01